BioCentury
ARTICLE | Clinical News

Organoselenium: Phase II start

April 16, 2007 7:00 AM UTC

Next quarter, ALT will start a Phase II trial in diabetic patients expressing the Haptoglobin 2-2 genotype. The company got an exclusive license to ALT-2074 from OXIS last week. ...